Stay updated on Vudalimab for Anaplastic/Hurthle Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Vudalimab for Anaplastic/Hurthle Thyroid Cancer Clinical Trial page.

Latest updates to the Vudalimab for Anaplastic/Hurthle Thyroid Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe study record history now includes a new revision entry v3.6.4, replacing the previous revision v3.6.3, reflecting an update to the release notes for the page.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedA new revision entry (v3.6.3) appears in the study history, replacing the previous revision (v3.6.2). This indicates an update to the study record's metadata.SummaryDifference0.1%

- Check37 days agoChange DetectedThe record history shows a newer page revision (v3.6.2) replacing the previous one (v3.6.0), indicating an update to the page's underlying software or layout.SummaryDifference0.1%

- Check51 days agoChange DetectedThe study history shows the recruitment status changing to not recruiting participants, clarifying that enrollment is closed; the record also notes a new version (Revision: v3.6.0) while the previous version (Revision: v3.5.5) was removed.SummaryDifference0.5%

- Check59 days agoChange DetectedA new revision (v3.5.5) has been added to the record history, indicating the study record has been updated. The previous revision (v3.5.4) was removed from the list.SummaryDifference0.1%

- Check80 days agoChange DetectedA new revision label v3.5.4 is added to the study record history, indicating an update to the page's version history. The previous revision v3.5.3 is removed from the visible history.SummaryDifference0.1%

Stay in the know with updates to Vudalimab for Anaplastic/Hurthle Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vudalimab for Anaplastic/Hurthle Thyroid Cancer Clinical Trial page.